apyrase has been researched along with Sezary-Syndrome* in 4 studies
4 other study(ies) available for apyrase and Sezary-Syndrome
| Article | Year |
|---|---|
CD39/CD73 dysregulation and adenosine metabolism contribute to T-cell immunosuppression in patients with Sézary syndrome.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphate; Apyrase; Humans; Immune Tolerance; Immunosuppression Therapy; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes | 2023 |
Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sézary syndrome.
Topics: 5'-Nucleotidase; Adenosine; Antibody-Dependent Cell Cytotoxicity; Antigens, CD; Apyrase; Cell Proliferation; Humans; Killer Cells, Natural; Sezary Syndrome; Skin Neoplasms | 2022 |
Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis.
Sézary syndrome (SS) is a rare and aggressive variant of cutaneous T-cell lymphoma. It is characterized by the copresence of CD4+ neoplastic lymphocytes, named Sezary cells, mainly in the blood, lymph nodes, and skin where they induce chronic inflammation that in turn impairs the patient's QOL and fuels neoplastic cells. SS is not readily cured, but immunotherapy is becoming an effective option for this lymphoma. In this study, we investigated, in a large cohort of patients with SS, the expression and function of the immune checkpoint molecule CD39, which degrades proinflammatory extracellular adenosine triphosphate. We showed that the SNP rs10748643 A/G within the ENTPD1 gene coding for the CD39 protein controls its expression level. Patients carrying the A/G‒G/G genotype showed a significantly higher frequency of clonal CD4+CD39+ SS cells than those carrying the A/A genotype. Different from other cancers, high CD39 expression correlates with a better prognosis. Comparing primary G/G with A/A lymphoma cells, we observed that G/G SS cells have a higher ability to degrade adenosine triphosphate, increased apoptotic susceptibility, and upon activation, reduced IL-2 production. Accordingly, CD39 enzymatic inhibition enhances SS cell viability and IL-2 production on activation. These results strongly suggest a special caution for SS treatment with therapeutic inhibitors of CD39. Topics: Adenosine Triphosphate; Apyrase; Cell Survival; Humans; Immune Checkpoint Proteins; Interleukin-2; Lymphocytes; Prognosis; Quality of Life; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes, Regulatory | 2022 |
Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of Sézary Syndrome Patients.
Topics: Antigens, CD; Apyrase; Biomarkers, Tumor; Biopsy, Needle; Case-Control Studies; Flow Cytometry; Humans; Immunohistochemistry; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Reference Values; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes; Tumor Burden | 2019 |